Efficacy of XXXX (Erivedge) for @entity1491 Involving the Orbit and Periocular Area.

@entity1 @entity1665 @entity5 @entity294 @entity189 @entity2473 @entity9658 @entity2752 @entity4838 @entity1142 @entity2342 @entity1491
PURPOSE:: Evaluate the effectiveness of @entity2752 in the management of @entity1491 with orbital extension and/or extensive periocular involvement. METHODS:: Retrospective chart review of 6 consecutive @entity1 with biopsy-proven orbital @entity1491 and 2 additional @entity1 with extensive @entity1491 who were treated with oral @entity2752 (150 mg/day) was performed. RESULTS:: Basal cell @entity189 extended in the orbit in 6 of 8 @entity1 (involving orbital bones in 1 @entity1 ), and 2 of 8 @entity1 had extensive periocular involvement (1 with @entity9658 ). @entity2752 therapy was the only treatment in 6 @entity1 , off-label neoadjuvant in 1 @entity1 , and adjuvant treatment in 1 @entity1 . @entity5 in all 4 @entity1 who received @entity2752 as sole treatment showed partial response with a mean 83% shrinkage in @entity5 size after a median of 7 months of therapy. In the 2 @entity1 receiving @entity2752 as neoadjuvant or adjuvant therapies, there was complete response after a median of 7 months of therapy and no evidence of clinical recurrence after discontinuing therapy for a median of 15 months. The 2 @entity1 with extensive periocular involvement experienced complete clinical response after a median 14 months of treatment. During treatment, the most common side effects were @entity2473 (75%) followed by @entity1665 (50%), @entity2342 (25%), @entity4838 , and episodes of @entity294 and @entity1142 (13%). CONCLUSIONS:: Basal cell @entity189 with orbital extension and extensive periocular involvement responds to @entity2752 therapy. The long-term prognosis remains unknown, and additional prospective studies are indicated.
